STAA

Business Context and Reporting Period

Company: STAAR Surgical Company
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 2, 2004
Business Overview: STAAR Surgical develops, manufactures, and distributes medical devices for minimally invasive ophthalmic surgery, including Intraocular Lenses (IOLs), the VISIAN ICL for refractive correction, and the AquaFlow device for glaucoma. The company operates as a single business segment with significant international operations, particularly in Germany and Switzerland.

Key Financial Metrics

Note: Q1 2003 cash balance shown is the ending balance for that quarter; beginning balance for Q1 2004 was $7,286.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 5.8% to $13.6 million. This increase was primarily driven by favorable foreign currency exchange rates (approx. $932,000 impact). On a constant currency basis, product sales actually declined due to reduced competitiveness of single and three-piece silicone IOLs.
• Operating Expenses: Total selling, general, and administrative expenses rose 8.7% to $8.3 million. Marketing and selling expenses increased 18.6% due to preparations for the U.S. launch of the VISIAN ICL. General and administrative expenses decreased 9.5% due to cost reductions and subsidiary closures.
• Profitability: The operating loss widened by 50.9% to $973,000, and the net loss increased 35.6% to $1.3 million. Gross margin compressed slightly to 53.9% due to increased costs for quality improvements and idle production capacity.
• Cash Flow: Net cash used in operating activities was $1.3 million, a significant deterioration from the $27,000 provided in the prior year. Cash and cash equivalents decreased by $1.8 million during the quarter.

Guidance, Outlook, Risks, and Contingencies

• FDA Warning Letters: The company received Warning Letters from the FDA in December 2003 and April 2004 regarding deficiencies in manufacturing and quality assurance at its Monrovia, CA facility. Until resolved, the company cannot receive approval for new products (specifically the ICL) and faces potential restrictions on existing domestic lines.
• Debt Covenant Violation: The company failed to meet a financial covenant under its Swiss credit facility regarding minimum equity levels. A waiver was obtained from the lender, but the company expects to remain in violation in the near term and is renegotiating terms.
• Product Launch: Management is heavily investing in the U.S. launch of the VISIAN ICL, which is approved in Europe and Canada but pending FDA approval in the U.S. Success is deemed critical for future profitability.
• Market Risks: The company faces risks from currency fluctuations (exposure to Euro, Swiss Franc, Australian Dollar), intense competition from larger firms (Alcon, Bausch & Lomb), and potential product recalls.
• Subsequent Event: On May 5, 2004, the company agreed to purchase an additional 10% interest in its Australian subsidiary for approximately $768,000.

Investor Verification Checklist

• FDA Resolution Status: Verify the current status of corrective actions taken in response to the FDA Warning Letters and any impact on the ICL approval timeline.
• Debt Covenant Compliance: Confirm the outcome of the renegotiation with the Swiss lender and the likelihood of future covenant waivers.
• ICL U.S. Launch: Assess the progress of marketing preparations and the regulatory pathway for the VISIAN ICL in the United States.
• Currency Impact: Monitor exchange rate trends, as a strengthening U.S. dollar could negatively impact reported revenues and gross profit from international operations.
• Core Product Decline: Evaluate the trajectory of sales for legacy silicone IOLs versus the uptake of new specialty lenses (Collamer, Toric) to determine if the revenue decline is stabilizing.